Li D, Tan R, Hernandez S, Reilly N, Bussberg C, Mansfield C. Patient preferences for unresectable hepatocellular carcinoma treatments: a discrete-choice experiment. Cancers. 2023 Feb 25;15(5):1470. doi: 10.3390/cancers15051470
Bhatia S, Nghiem P, Veeranki SP, Vanegas A, Lachance K, Tachiki L, Chiu K, Boller E, Bharmal M. Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study. J Immunother Cancer. 2022 Aug;10(8):e004904. doi: 10.1136/jitc-2022-004904
Bhatia S, Nghiem P, Veeranki SP, Vanegas A, Lachance K, Tachiki L, Chiu K, Boller E, Bharmal M. Real-world clinical outcomes among patients with advanced Merkel cell carcinoma treated with avelumab in academic medical centers in the United States. Poster presented at the SITC 2021 36th Anniversary Annual Meeting; November 9, 2021. Washington, DC. [abstract] J Immunother Cancer. 2021 Nov; 9(Suppl 2):A658.
Ward MA, Fang G, Richards KL, Walko CM, Earnshaw SR, Happe LE, Blalock S. Treatment interruption and regimen change in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. JHEOR. 2015 Apr;2(2):181-91.
Davis KL, Gutierrez B, Zyczynski T, Kaye JA. Real-world treatment patterns in men with castration-resistant prostate cancer receiving docetaxel. JHEOR. 2015 Jan 6;2(2):119-30. doi: 10.36469/9894
Sorensen HT, Sabroe S, Olsen J, Rothman KJ, Gillman MW, Fisher P. Birth weight as a predictor of young men's intelligence. A historical cohort study. Ugeskr Laeger. 1999 Feb 8;161(6):791-3.